HHCYH-33 is under clinical development by Shanghai Haihe Biopharma and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HHCYH-33’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HHCYH-33 overview
HHCYH-33 is under development for the treatment of solid tumor including metastatic esophageal, gastroesophageal junction squamous cell carcinoma, ovarian cancer, prostate cancer, breast cancer, cervical cancer, head and neck squamous cell carcinoma, gastric cancer, fallopian tube cancer, HER-2 negative breast cancer, endometrial cancer, primary peritoneal cancer and PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (PRVM). It is administered through oral route as a tablet. The drug candidate acts by targeting phosphatidylinositol 3-kinase alpha (PI3K-alpha).
Shanghai Haihe Biopharma overview
Shanghai Haihe Biopharma (Haihe Biopharma) is a biotechnology company. Haihe Biopharma’s product portfolio comprises glumetinib, RMX3001, CYH33, AL3810, HH2853, HH2710, HH30134, HH2301, HH3806, HHHN, HHANT, HHOS, ON101 AND HHMT. The company offers its products in the therapeutic areas of lung cancer, breast cancer, gastric cancer, solid tumor and Lymphoma among others. Haihe Biopharma is headquartered in Shanghai, Pu Dong, China.
For a complete picture of HHCYH-33’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
